Overview

Safety and PK Study of MP-424 to Treat Chronic Hepatitis C

Status:
Completed
Trial end date:
2008-10-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, pharmacokinetics and HCV(Hepatitis C virus) RNA (Ribonucleic Acid) kinetics after administration of MP-424 to patients with chronic hepatitis C.
Phase:
Phase 1
Details
Lead Sponsor:
Mitsubishi Tanabe Pharma Corporation
Collaborator:
Vertex Pharmaceuticals Incorporated